The authors review the nature of the proposal by the FDA for the regulation of next-generation sequencing and laboratory-developed tests in clinical medicine and offer thoughts on what is needed to protect consumers and foster innovation.
No takes yet. Share an insight, caveat, or question.
Evans et al. (2015) studied this question.